Community Clinical Research, Inc.

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Schizophrenia5 trials
• Bipolar disorder4 trials
• Depression2 trials

Phase

• Phase 35 trials
• Phase 24 trials
• Phase 11 trial
• Phase 2/31 trial

Status

• Completed7 trials
• Terminated2 trials
• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Biohaven Therapeutics Ltd.2 trials
• Otsuka Pharmaceutical Development & Commercialization, Inc.2 trials
• Boehringer Ingelheim1 trial
• Janssen Research & Development, LLC1 trial
• Karuna Therapeutics, Inc., a Bristol Myers Squibb company1 trial
• and 4 more

Running trials

• Recruiting

  A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

  NCT07615426· Phase 1· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

  NCT06894212· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Schizophrenia1 recruiting

Closed trials

• Completed

  Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

  NCT07046494· Phase 2· Rapport Therapeutics Inc.· Source

• Completed

  Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

  NCT06836063· Phase 2· Suven Life Sciences Limited· Source

• Terminated

  BHV-7000 Open-Label Extension Bipolar Mania Study

  NCT06423794· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  BHV-7000 Acute Treatment of Bipolar Mania

  NCT06419582· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Completed

  Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

  NCT05779241· Phase 3· Lyndra Inc.· Source

• Completed

  A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

  NCT05593029· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Terminated

  A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

  NCT05227209· Phase 3· Sumitomo Pharma America, Inc.· Source

• Completed

  A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

  NCT04846868· Phase 3· Boehringer Ingelheim· Source